Loading...

DARE DARE BIOSCIENCE INC Capital Structure Changes 8-K Filing

DR B

DR

DARE BIOSCIENCE INC

(DARE)

2026 8-K

Financial Results Update

Equity Offering Completed

Investor Unit Closure

Corporate Presentation Update

New Stock Issuance

Corporate Update

License Termination

Financial Results

Corporate Presentation

Financial Results Announced

Equity Offerings

Clinical Trials

Rights Offerings

Investor Meetings

Earnings Releases

Nasdaq Compliance Extension

Financial Results

Nasdaq Delisting Notice

Investor Presentation

Corporate Presentation

Clinical Study Plans

Financial Results

Investor Presentation

Funding Agreement

Stock Purchase Agreement

Financial Results

Compliance regained with Na...

Reverse Stock Split

Annual Meeting of Stockholders

Earnings Report

Agreements with XOMA

Financial Results Announcement

Management Changes

Corporate Presentation

Royalty Interest Financing ...

Phase 1 Clinical Study Results

Changes in Registrant's Cer...

Financial Results Announcement

Phase 2b RESPOND study resu...

Commercial Milestone Achiev...

Financial Results and Audit...

Forced Delisting

Contract Renewal

Annual Meeting of Stockholders

Clinical Trial Results

Earnings Reports

Sales Agreement

Earnings Reports

Presentation Release

Presentation Release

By-laws Amendment

Compliance with Nasdaq Mini...

Clinical Study Results

External Links:

Dare Bioscience, Inc. reported that on March 16, 2026, it closed a Regulation A offering of 43,050 Investor Units at $5.00 each, totaling 43,050 shares of Series A Preferred Stock and warrants for 86,100 common shares.

AI Assistant

DARE BIOSCIENCE INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.